【招银国际】We expect prudent guidance but decent margins.pdf

Expecting inline 3Q revenue growth with upside coming from bottom line

Expect $3.5bn CB dilutive effect to be short-term

Expect domestic business to rebound from 2025

Turnaround is here but weaker than expected

Expect Shengyi to enter Nvidia supply chain in 2024

China Pharmaceutical & Healthcare - Expecting global funding recovery in the coming quarters

China Pharmaceutical & Healthcare: Expecting global funding recovery in the coming quarters

2Q loss reduction trend better than expectation

China Property Sector – Property+ Weekly： Can we expect post-CNY recovery？

1H23 Preview: weak revenue amid industry headwinds; expect smartphone recovery in 2H23E